The University of Minnesota Medical School announced today its plans to participate in a Phase 3 COVID-19 clinical trial in the fight against the novel coronavirus. The clinical trial will test the safety and effectiveness of an investigational vaccine developed by U.S. biotechnology company Novavax, Inc., called NVX-CoV2373. Novavax is a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases.
University of Minnesota Medical School researchers have developed two new rapid diagnostic tests for COVID-19 – one to detect COVID-19 variants and one to help differentiate with other illnesses that have COVID-19-like symptoms. The findings were recently published in the journal Bioengineering.